Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1785-1791

  Löscher, Wolfgang ^a,b   Langer, Oliver ^c,d  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Center for Systems Neuroscience Hannover   (Austria)

^c AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiepileptic drugs; Brain imaging; Multidrug transporters; Positron emission tomography; Tariquidar; Verapamil

Indexed keywords

ANTICONVULSIVE AGENT; CARVEDILOL; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DOPAMINE TRANSPORTER; ELACRIDAR; GLYCOPROTEIN P; LANIQUIDAR; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHENYTOIN; TARIQUIDAR; TRACER; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; DISTRIBUTION VOLUME; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TRANSPORT; EPILEPSY; GENETIC VARIABILITY; HUMAN; INFLAMMATION; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOLUNTEER;

ANIMALS; ANTICONVULSANTS; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HUMANS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY;

EID: 77958016107     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928095     Document Type: Article

References (59)

1. Schinkel, A. H.; Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55, 3-29.
2. Elsinga, P. H.; Hendrikse, N. H.; Bart, J.; Vaalburg, W.; van Waarde, A. PET Studies on P-glycoprotein function in the bloodbrain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des., 2004, 10, 1493-1503.
3. Upton, R. N. Cerebral uptake of drugs in humans. Clin. Exp. Pharmacol. Physiol., 2007, 34, 695-701.
4. Gottesman, M. M.; Ling, V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett., 2006, 580, 998-1009.
5. Miller, D. S.; Bauer, B.; Hartz, A. M. S. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy. Pharmacol. Rev., 2008, 60, 196-209.
6. Löscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci., 2005, 6, 591-602.
7. Löscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol., 2005, 76, 22-76.
8. Kwan, P.; Brodie, M. J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia, 2005, 46, 224-235.
9. Tishler, D. M.; Weinberg, K. T.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia, 1995, 36, 1-6.
10. Abbott, N.J.; Khan, E.U.; Rollinson, C.M.S.; Reichel, A.; Janigro, D.; Dombrowski, S.M.; Dobbie, M.S.; Begley, D.J. Drug resistance in epilepsy: the role of the blood-brain barrier. In: Mechanisms of Drug Resistance in Epilepsy. Lessons from Oncology. Ling, V. Ed.; Wiley: Chichester, 2002, pp. 38-46.
11. Löscher, W.; Potschka, H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther., 2002, 301, 7-14.
12. Sisodiya, S. M. Mechanisms of antiepileptic drug resistance. Curr. Opin. Neurol., 2003, 16, 197-201.
13. Hughes, J. R. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol. Res., 2008, 30, 920-925.
14. Schmidt, D. Löscher, W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr., 2009, 9, 47-52.
15. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 2007, 52, 333-346.
16. Cucullo, L.; Hossain, M.; Rapp, E.; Manders, T.; Marchi, N.; Janigro, D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia, 2007, 48, 505-516.
17. Sills, G. J. Means, motive, and opportunity: establishing culpability in pharmacoresistant epilepsy. Epilepsy Curr., 2007, 7, 51-53.
18. Luna-Tortós, C.; Fedrowitz, M.; Löscher, W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology, 2008, 55, 1364-1375.
19. Sharma, V. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjug. Chem., 2004, 15, 1464-1474.
20. Weber, S. and Bauer, A. Small animal PET: aspects of performance assessment. Eur. J Nucl. Med. Mol. Imaging, 2004, 31, 1545-1555.
21. Kannan, P.; John, C.; Zoghbi, S. S.; Halldin, C.; Gottesman, M. M.; Innis, R. B.; Hall, M. D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther., 2009, 86, 368-377.
22. Vaalburg, W.; Hendrikse, N. H.; Elsinga, P. H.; Bart, J.; van Waarde, A. P-glycoprotein activity and biological response. Toxicol. Appl. Pharmacol., 2005, 207, 257-260.
23. Hendrikse, N. H.; Schinkel, A. H.; de Vries, E. G.; Fluks, E.; van der Graaf, W. T.; Willemsen, A. T.; Vaalburg, W.; Franssen, E. J. Complete in vivo reversal of P-glycoprotein pump function in the bloodbrain barrier visualized with positron emission tomography. Br. J. Pharmacol., 1998, 124, 1413-1418.
24. Sasongko, L.; Link, J. M.; Muzi, M.; Mankoff, D. A.; Yang, X.; Collier, A. C.; Shoner, S. C.; Unadkat, J. D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther., 2005, 77, 503-514.
25. Lubberink, M.; Luurtsema, G.; van Berckel, B. N.; Boellaard, R.; Toornvliet, R.; Windhorst, A. D.; Franssen, E. J.; Lammertsma, A. A. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J. Cereb. Blood Flow Metab., 2007, 27, 424-433.
26. Luurtsema, G.; Molthoff, C. F.; Schuit, R. C.; Windhorst, A. D.; Lammertsma, A. A.; Franssen, E. J. Evaluation of (R)-[11C] verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl. Med. Biol., 2005, 32, 87-93.
27. Zoghbi, S. S.; Liow, J. S.; Yasuno, F.; Hong, J.; Tuan, E.; Lazarova, N.; Gladding, R. L.; Pike, V. W.; Innis, R. B. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J. Nucl. Med., 2008, 49, 649-656.
28. Abrahim, A.; Luurtsema, G.; Bauer, M.; Karch, R.; Lubberink, M.; Pataraia, E.; Joukhadar, C.; Kletter, K.; Lammertsma, A. A.; Baumgartner, C.; Müller, M.; and Langer, O. Peripheral metabolism of (R)- [11C]verapamil in epilepsy patients. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 116-123.
29. Lazarova, N.; Zoghbi, S. S.; Hong, J.; Seneca, N.; Tuan, E.; Gladding, R. L.; Liow, J. S.; Taku, A.; Innis, R. B.; Pike, V. W. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging Pgp function. J. Med. Chem., 2008, 51, 6034-6043.
30. Liow, J. S.; Kreisl, W.; Zoghbi, S. S.; Lazarova, N.; Seneca, N.; Gladding, R. L.; Taku, A.; Herscovitch, P.; Pike, V. W.; Innis, R. B. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J. Nucl. Med., 2009, 50, 108-115.
31. Kuntner, C.; Bankstahl, J. P.; Bankstahl, M.; Stanek, J.; Wanek, T.; Stundner, G.; Karch, R.; Brauner, R.; Meier, M.; Ding, X.; Müller, M.; Löscher, W.; Langer, O. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37, 942-953.
32. Fox, E.; Bates, S. E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther., 2007, 7, 447-459.
33. Bankstahl, J. P.; Kuntner, C.; Abrahim, A.; Karch, R.; Stanek, J.; Wanek, T.; Wadsak, W.; Kletter, K.; Müller, M.; Löscher, W.; Langer, O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J. Nucl. Med., 2008, 49, 1328-1335.
34. Wagner, C. C.; Bauer, M.; Karch, R.; Feurstein, T.; Kopp, S.; Chiba, P.; Kletter, K.; Löscher, W.; Müller, M.; Zeitlinger, M.; Langer, O. A pilot study to assess the efficacy of tariquidar to in-hibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J. Nucl. Med., 2009, 50, 1954-1961.
35. Wong, D. F.; Yung, B.; Dannals, R. F.; Shaya, E. K.; Ravert, H. T.; Chen, C. A.; Chan, B.; Folio, T.; Scheffel, U.; Ricaurte, G. A. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse, 1993, 15, 130-142.
36. Ginovart, N.; Wilson, A. A.; Meyer, J. H.; Hussey, D.; Houle, S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J. Cereb. Blood Flow Metab., 2001, 21, 1342-1353.
37. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.; Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res., 2008, 25, 1469-1483.
38. Farde, L.; Hall, H.; Pauli, S.; Halldin, C. Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse, 1995, 20, 200-208.
39. Bauer, F.; Kuntner, C.; Bankstahl, J.P.; Wanek, T; Bankstahl, M.; Stanek, J.; Mairinger, S.; Dörner, B.; Löscher, W.; Müller, M.; Erker, T.; Langer, O. Synthesis and in vivo evaluation of 11C-tariquidar, a PET radiotracer based on a third-generation Pgp inhibitor. Bioorg. Med. Chem. 2010, in press (DOI 10.1016/j.bmc.2010.06.057).
40. Dörner, B.; Kuntner, C.; Bankstahl, J. P.; Bankstahl, M.; Stanek, J.; Wanek, T.; Stundner, G.; Mairinger, S.; Löscher, W.; Müller, M.; Langer, O.; Erker, T. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the bloodbrain barrier. J. Med. Chem., 2009, 52, 6073-6082.
41. Luurtsema, G.; Schuit, R. C.; Klok, R. P.; Verbeek, J.; Leysen, J. E.; Lammertsma, A. A.; Windhorst, A. D. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol., 2009, 36, 643-649.
42. van Waarde, A.; Ramakrishnan, N. K.; Rybczynska, A. A.; Elsinga, P. H.; Berardi, F.; de Jong, J. R.; Kwizera, C.; Perrone, R.; Cantore, M.; Sijbesma, J. W.; Dierckx, R. A.; Colabufo, N. A. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J. Med. Chem., 2009, 52, 4524-4532.
43. Eckelman, W. C.; Mathis, C. A. Targeting proteins in vivo: in vitro guidelines. Nucl. Med. Biol., 2006, 33, 161-164.
44. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol., 1999, 128, 403-411.
45. Martin, C.; Berridge, G.; Higgins, C. F.; Mistry, P.; Charlton, P.; Callaghan, R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol., 2000, 58, 624-632.
46. Wang, J. H.; Scollard, D. A.; Teng, S.; Reilly, R. M.; Piquette-Miller, M. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J Nucl. Med., 2005, 46, 1537-1545.
47. Gomes, C. M.; Abrunhosa, A. J.; Pauwels, E. K.; Botelho, M. F. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin. Cancer Biother. Radiopharm., 2009, 24, 215-227.
48. Langer, O.; Bauer, M.; Hammers, A.; Karch, R.; Pataraia, E.; Koepp, M. J.; Abrahim, A.; Luurtsema, G.; Brunner, M.; Sunder-Plassmann, R.; Zimprich, F.; Joukhadar, C.; Gentzsch, S.; Dudczak, R.; Kletter, K.; Müller, M.; Baumgartner, C. Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R-[11C] verapa-mil. Epilepsia, 2007, 48, 1774-1784.
49. Löscher, W.; Klotz, U.; Zimprich, F.; Schmidt, D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 2009, 50, 1-23.
50. Brunner, M.; Langer, O.; Sunder-Plassmann, R.; Dobrozemsky, G.; Müller, U.; Wadsak, W.; Krcal, A.; Karch, R.; Mannhalter, C.; Dudczak, R.; Kletter, K.; Steiner, I.; Baumgartner, C.; Müller, M. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther., 2005, 78, 182-190.
51. Takano, A.; Kusuhara, H.; Suhara, T.; Ieiri, I.; Morimoto, T.; Lee, Y. J.; Maeda, J.; Ikoma, Y.; Ito, H.; Suzuki, K.; Sugiyama, Y. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med., 2006, 47, 1427-1433.
52. Basic, S.; Hajnsek, S.; Bozina, N.; Filipcic, I.; Sporis, D.; Mislov, D.; Posavec, A. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across blood-brain barrier in patients with generalized epilepsy. Seizure Eur. J. Epilepsy, 2008, 17, 524-530.
53. Stavchansky, S. A.; Tilbury, R. S.; McDonald, J. M.; Ting, C. T.; Kostenbauder, H. B. In vivo distribution of carbon-11 phenytoin and its major metabolite, and their use in scintigraphic imaging. J. Nucl. Med., 1978, 19, 936-941.
54. Roeda, D.; Westera, G. The synthesis of some 11C-labelled antiepileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturates. Int. J. Appl. Radiat. Isot., 1981, 32, 843-845.
55. Baron, J. C.; Roeda, D.; Munari, C.; Crouzel, C.; Chodkiewicz, J. P.; Comar, D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology, 1983, 33, 580-585.
56. Brandt, C.; Bethmann, K.; Gastens, A. M.; Löscher, W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis., 2006, 24, 202-211.
57. Bankstahl, J. P.; Löscher, W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res., 2008, 82, 70-85.
58. Löscher, W. Animal models of drug-refractory epilepsy. In: Models of Seizures and Epilepsy. Pitkänen, A.; Schwartzkroin, P. A.; Moshe, S. L. Eds.; Elsevier: San Diego, 2006, pp 551-566.
59. Volk, H. A.; Löscher, W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain, 2005, 128, 1358-1368.